Related Experiment Video

Updated: May 27, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Infant respiratory syncytial virus (RSV) immunisation coverage in an Australian regional area, 1 May 2024 - 31

William Roughan1, Brett Cavanagh-Ochiai2, Donna Barnekow2

  • 1Department of Paediatrics, Sunshine Coast University Hospital, Queensland, Australia.

Communicable Diseases Intelligence (2018)
|May 25, 2026
PubMed

Insights

Australia

Area of Science:

  • Pediatrics
  • Immunology
  • Public Health

Background:

  • Respiratory Syncytial Virus (RSV) poses a significant health burden on infants.
  • Australia introduced nirsevimab (neonatal) and Abrysvo (antenatal) for RSV immunisation.
  • Understanding the impact of these new immunisations on infant protection is crucial.

Purpose of the Study:

  • To evaluate the uptake and composition of RSV immunisations in infants.
  • To assess the impact of introducing Abrysvo on nirsevimab-only coverage.
  • To compare RSV immunisation coverage with national and international benchmarks.

Main Methods:

  • Retrospective cohort study of infants born at Sunshine Coast University Hospital (May 2024 - Oct 2025).
  • Analysis of RSV immunisation status (nirsevimab, Abrysvo, or both).
  • Tracking immunisation composition changes following Abrysvo's introduction.

Main Results:

  • 71.7% of 5,116 infants received valid RSV immunisation.
  • Introduction of Abrysvo shifted protection from nirsevimab-only to Abrysvo-only.
  • Overall RSV coverage remained stable but lagged European benchmarks; Abrysvo maintained, not improved, protection.

Conclusions:

  • RSV immunisation uptake in Australia shows a shift in protection methods.
  • Further investigation into immunisation uptake barriers is needed to optimize infant protection.
  • Current coverage rates necessitate strategies to meet or exceed international standards.

Keywords:
RSVimmunisationimmunisation coveragepaediatricspublic healthrespiratory syncytial virusvaccination

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Vaccinations01:51

Vaccinations

Overview
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...